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Abstract
Background: Cisplatin is a potent antitumor agent. However, toxicity and primary and secondary resistance are
major limitations of cisplatin-based chemotherapy, leading to therapeutic failure. We have previously reported that
mono-sulfonamide platinum complexes have good antitumor activity against different tumoral cell lines and with
a different and better cytotoxic profile than cisplatin. Besides, N-sulfonamides have been used extensively in
medicinal chemistry as bactericides, anticonvulsant, inhibitors of the carbonic anhydrase, inhibitors of histone
deacetylases, and inhibitors of microtubule polymerization, among others.
Methods: We aimed to compare the cytotoxic effects of cisplatin and a trans-sulfonamide-platinum-complex (TSPC),
in two human melanoma cell lines that differ in their TP53 status: SK-MEL-5, TP53 wild type, and SK-MEL-28, TP53
mutated. We performed cytotoxicity assays with both drugs, alone and in combination, cell cycle analyses, western
blotting and immunoprecipitation, and fluorescence immunocytochemistry.
Results: TSPC had similar antiproliferative activity than cisplatin against SK-MEL-5 (3.24 ± 1.08 vs 2.89 ± 1.12 μM) and
higher against SK-MEL-28 cells (5.83 ± 1.06 vs 10.17 ± 1.29 μM). Combination of both drugs inhibited proliferation in
both cell lines, being especially important in SK-MEL-28, and showing a synergistic effect. In contrast to cisplatin, TSPC
caused G1 instead G2/M arrest in both cell lines. Our present findings indicate that the G1 arrest is associated with the
induction of CDKN1A and CDKN1B proteins, and that this response is also present in melanoma cells containing TP53
mutated. Also, strong accumulation of CDKN1A and CDKN1B in cells nuclei was seen upon TSPC treatment in
both cell lines.
Conclusions: Overall, these findings provide a new promising TSPC compound with in vitro antitumor activity
against melanoma cell lines, and with a different mechanism of action from that of cisplatin. Besides, TSPC
synergism with cisplatin facilitates its potential use for co-treatment to reduce toxicity and resistance against
cisplatin. TSPC remains
a promising lead compound for the generation of novel antineoplastic agent and to explore its synergism
with other DNA damaging agents.
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Background
Cisplatin (cis-diamminedichloroplatinum(II) or CDDP)
is one of the most successful traditional antitumoral
metal compounds used in oncology. Its mode of action
is mediated by its interaction with DNA to form DNA
adducts, which activate several signal transduction
pathways leading to cell death [1, 2]. However, it is asso-
ciated with different adverse side effects, such as
dose-limiting nephrotoxicity, peripheral neuropathy,
electrolyte disturbance, tinnitus and hearing loss [3]. In
addition, primary or secondary resistance to CDDP may
occur, leading to therapeutic failure [2, 4]. Many plat-
inum compounds have been designed with the aim to
broaden the spectrum of activity, reduce side effects,
and overcome resistance to CDDP [5–8].
On the other hand, N-sulfonamides have been used
extensively in medicinal chemistry as inhibitors of
histone deacetylases and microtubule polymerization,
among other targets [9–11]. Besides the large number of
publications concerning to the use of sulfonamides, the
synthesis of platinum compounds containing sulfon-
amides in their structure has been scarce. The most
promising results are given by those compounds which
activate alternative signaling pathways [12, 13]. There-
fore, research on new metallodrugs remains an area of
interest, especially those with different mechanisms of
action from CDDP.
Recently, we published the synthesis and evaluation of
a series of trans-sulfonamide platinum complexes
showing antitumor activity [14]. Among these com-
pounds, trans-Dichlorido [(rac)-2-(5-(dimethylamino)-
naphthalene-1-sulfonamido)cyclohexylamino] (dimethyl-
sulfoxide)platinum(II) (hereinafter TSPC), (Fig. 1) demonstrated
similar or superior activity than CDDP against a panel
of tumor cell lines, including melanoma. Melanoma is
a particularly aggressive cancer that has poor progno-
sis due to resistance to multiple chemotherapy
regimens, including in most cases CDDP [15, 16].
This highlights the urgency of implementing treatment
strategies for melanoma with more effective and less toxic
novel drugs.
Therefore, we decided to study several mechanistics
aspects of TSPC in two melanoma cell lines with a
different TP53 status: SK-MEL-5 (TP53 wild-type) and
SK-MEL-28 (TP53 mutated) [17]. TP53 is a tumor sup-
pressor protein that facilitates antitumor drug response
using a variety of key cellular functions, including cell
cycle arrest, senescence, and apoptosis [18], whose role
in the mode of action of CDDP has been extensively
described [1]. These functions usually cease once TP53
mutates, as occurs in nearly 50% of cancers, and some
TP53 mutants even exhibit gain-of-function effects,
which can lead to even greater drug resistance [18]. It is
therefore important to test the effectiveness of new
drugs in TP53 mutants.
In this study, we show the in vitro antitumor activity
of TSPC and CDDP in these melanoma cell lines and
mechanistic differences in cell cycle effects. We also aim
to explore if these differential effects might be used as a
basis for a synergism between both compounds.
Methods
Cell lines and reagents
Human melanoma cell lines SK-MEL-5 and SK-MEL-28
were obtained from American Type Culture Collection
(ATCC, Manassas, VA) in February 2010. Low passage
cells were cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum, 100 U/mL penicillin,
100 μg/mL streptomycin and 2 mM L-glutamine, under
standard culture conditions (37 °C, 95% humidified air
and 5% CO2). RPMI 1640 and other culture materials
were from Lonza Ltd. (Verviers, BEL). TSPC was synthe-
sized and characterized in the Inorganic Chemistry
Department of the Universidad Autónoma de Madrid
(Spain), as previously reported [14]. CDDP was obtained
from Selleck Chemicals LLC (Houston, TX). Drugs were
dissolved in dimethyl sulfoxide (DMSO) at 100 mM of
stock solution, and stored at −20 °C until use.
Proliferation assays
Briefly, cells were seeded in a 96-well flat-bottom plate
at 5000 cells/well and cultured for 24 h prior to expos-
ure to CDDP or TSPC at varying concentrations, from 0
to 100 μM for 72 h. For combination assays, cells were
treated with CDDP ranging from 0.5 to 10 μM and two
different doses of TSPC (1 and 5 μM). Results were
expressed as a percentage relative to vehicle-treated con-
trol (0.1% DMSO was added to untreated cells). Viability
was determined using the WST-1 method (Roche,
Mannheim) following the manufacter’s instructions. The
50% inhibitory concentration (IC50) was calculated by
nonlinear regression fit of the mean values of the data
Fig. 1 trans-Dichlorido [(rac)-2-(5-(dimethylamino)naphthalene-1-
sulfonamido)cyclohexylamino] (dimethylsulfoxide)platinum(II)
compound (TSPC). Chemical Formula: C20H31Cl2N3O3PtS2 Molecular
Weight: 691.5924 g/mol
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obtained in at least three independent experiments using
GraphPad Prism software version 5.0 (San Diego, CA).
The type of drug interaction was analysed by the
Chou-Talalay method [19]. This method provides a com-
bination index (CI) that allows quantitative determin-
ation of drug interactions, where CI < 1, 1, and >1
indicate synergism, additive effect or antagonism,
respectively, considering synergism as more than addi-
tive effect and antagonism as less than additive effect.
This method also provides a dose reduction index (DRI)
that measure how many-fold the dose of a drug can be
reduced in combination with respect to the drug alone.
The CI and the DRI were calculated using the CompuSyn
software (Comb ComboSyn Inc, Paramus, NJ).
Cell cycle and apoptosis analysis
Cells were treated for 24 h with equimolar concentra-
tions of either CDDP or TSPC. The cell cycle progres-
sion was examined by flow cytometry after staining with
propidium iodide (PI). DNA content and cell cycle
analyses were performed by using a FACScalibur flow
cytometer and the CellQuest software (Becton Dickinson
Biosciences). Apoptosis was studied with the APO-
BrdUTunel assay kit (Life Technologies Inc. Gaithers-
burg, MD) following the experimental protocol provided
by the manufacturer, and analyzed with a FACScalibur
flow cytometer and the CellQuest software (BD
Biosciences). All experiments were performed in triplicate.
Western blot and immunoprecipitation assays
Cells untreated (control) or treated with equimolar con-
centrations of either CDDP or TSPC for 24 h were lysed
with MCL1 lysis buffer in the presence of protease and
phosphatase cocktail inhibitor (Sigma-Aldrich Co. LLC,
St Louis, MO) following the manufacter’s protocol. Total
protein concentrations were determined using the BCA
protein assay kit (Thermo Scientific Meridian Rd, Rock-
ford, IL). Protein lysates (30 μg) were subjected to
SDS-PAGE on 15% polyacrylamide gel. The separated
proteins were transferred on to PVDF membrane
followed by blocking with 5% non-fat milk powder (w/v)
in TTBS (10 mM Tris, 100 mM NaCl, 0.1% Tween 20).
Membranes were probed for the protein levels of TP53,
CDKN1A (p21Cip1), CDKN1B (p27Kip1), CDKN2B
(p15INK4b), CDK2, CDK4, CCND1 (Cyclin D1), CCNE2
(Cyclin E2), phospho-CDK1 (P-cdc2) and GAPDH using
specific primary antibodies (Cell Signaling Tech Inc,
Danvers, MA) diluted 1/1000 in blocking solution
followed by peroxidase-conjugated appropriate second-
ary antibody (Santa Cruz Biotechnology Inc, Dallas, TX),
and visualized by Immun-Star WesternC kit (Bio-Rad)
detection system. Results were scanned with Image
Quant LAS 4000 Imaging densitometer and quantify
with Image Quant TL software (GE healthcare, Life
Sciences). To ensure that control cells gave reproducible
baseline protein levels, we carefully maintained cells cul-
tures in a constant semiconfluent and logarithmically
growing state throughout each experiment.
Pierce Classic IP Kit (Thermo Scientific) was used for
immunoprecipitation assays, and manufacturer’s instruc-
tions were followed. Thereby, 1 mg of protein was
immunoprecipitated using CDK2 primary antibody (Cell
Signaling Tech Inc, Danvers, MA). The immune
complex eluted was subjected to SDS-PAGE and trans-
blotted into PVDF membranes as described above.
Membranes were probed for the protein levels of CDK2,
CDKN1A and CDKN1B.
Fluorescence immunocytochemistry
Cells were cultured in coverslip glasses for 24 h with equi-
molar concentration of either CDDP or TSPC. Untreated
cells were used as control. After exposure to the drugs,
cells were fixed with 4% formaldehyde and permeabilized
with PBS/triton (0.1%). For immunofluorescence labeling,
cells were incubated with anti-human CDKN1A (1:1000)
or CDKN1B (1:1000) monoclonal antibodies (Cell Signal-
ing Tech Inc, Danvers, MA) followed by a secondary anti-
body conjugated to Alexa Fluor 488 (Life Technologies
Inc; Gaithersburg, MD). Nuclei were stained with 2-(4-
amidinophenyl)-1H-indole-6-carboxamidine (DAPI) (Life
Technologies Inc. Gaithersburg, MD). Images from six to
ten fields per sample of at least three independent experi-
ments were taken with a LSM 510 Meta Confocal
Microscope (Zeiss, Germany).
Recovery experiments
To study the effects of duration of platinum exposure on
cell proliferation, cells were treated with CDDP or TSPC
at their corresponding IC50 for 72 h, or with CDDP
1 μM (SK-MEL-5) or 3 μM (SK-MEL-28) and TSPC 1 or
5 μM in combination assays. After this time, cells were
washed with PBS and put in drug-free medium to
recover. Viable cell number was assessed with Trypan blue
and a Neubauer chamber for 7 days of recovery.
Statistical analysis
Results are expressed as the mean ± SD, and data are
representative of at least three different experiments.
Analysis of variance (ANOVA) one way, followed by
Dunnett’s t-test was used to examine differences be-
tween groups. For recovery experiments, cell growth was
fit to a Gompertz function, typical of cell growth and
characterized by a lag period, an exponential and a sat-
uration phase. All the statistical tests were conducted at
the two-side 0.05 level of significance.
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Results
TSPC inhibits growth and induces G1 arrest in human
melanoma SK-MEL-5 and SK-MEL-28 cells
Based on our promising previous work with TSPC [14]
we decided to study its effect in two melanoma cell lines:
SK-MEL-5 (TP53 wild-type) and SK-MEL-28 (TP53
mutated). First, we analysed TSPC antiproliferative activ-
ity. As shown in Fig. 2a, TSPC treatment inhibited the
growth of human melanoma SK-MEL-5 and SK-MEL-28
cells in a dose-dependent manner. The IC50 of this com-
pound (3.24 ± 1.08 μM) was similar to the one obtained
with CDDP (2.89 ± 1.12 μM) in SK-MEL-5, and signifi-
cantly lower (p < 0.05) in SK-MEL-28 (5.83 ± 1.06 μM vs
10.17 ± 1.29 μM).
Next, we examined its effect on cell cycle progression
and in apoptosis induction. Consistent with the results
on cell growth inhibition, TSPC treatment for 24 h
induced a significant (p < 0.05) increment of cell number
in G1 phase in both melanoma cell lines (Fig. 2b),
whereas CDDP treatment induced S arrest, as has been
previously described elsewhere [2]. Apoptosis was not
observed by TUNEL assay after 24 h treatment with
neither CDDP nor TSPC, which is consistent with the
subG1 cell population identified in cell cycle analyses
(Figs. 2b and c). These effects were apparent in both
cell lines after a 24-h exposure to any of the two
compounds.
Effect of TSPC on G1 cell cycle regulators
Based on the G1 arrest induced by TSPC in both cell
lines, we assessed the effect of this compound on the cell
cycle regulatory molecules that play important roles in
G1 phase of cell cycle progression. TP53 is the most
important tumor suppressor protein associated with the
Fig. 2 Effect of CDDP and TSPC on melanoma cell lines. a Log-dose response curves for SK-MEL-5 and SK-MEL-28 cells following treatment with
CDDP or TSPC at 72 h. b Distribution of cells between cell cycle phases after CDDP and TSPC exposure. (*, p < 0.05). c Apoptotic effect of CDDP
and TSPC evaluated by APO-BrDUTunel assay. The experiments were carried out in triplicate. The results are shown as the mean ± standard
deviation. d Effect of CDDP and TSPC in cell cycle regulatory proteins TP53, CDKN1A, CDKN1B, CDKN2B, CDK2, CDK4, CCND1 (cyclin D1), CCNE2
(cyclin E2), and P-CDK1 as determined by Western blot analysis. GAPDH is shown as loading control
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G0-G1 arrest in cell cycle, and a key protein in CDDP
mode of action and resistance. Since SK-MEL-28 has a
mutation in TP53, we also examined the protein expres-
sion of the cyclin-CDK inhibitors (CKIs) CDKN1A
(p21Cip1), CDKN1B (p27Kip1), and CDKN2B (p15INK4b).
Western blot analysis showed that TSPC treatment
strongly increased the protein levels of CDKN1A and
CDKN1B and had no effect on TP53 levels in both cell
lines (Fig. 2d). The observed strong induction in
CDKN1A and CDKN1B protein levels by TSPC was not
due to an overall change in protein levels as confirmed
by probing the same membranes with GAPDH antibody
(Fig. 2d). Thus, treatment of SK-MEL-5 and SK-MEL-28
cells with TSPC caused an increased in CDKN1A and
CDKN1B expression, with correlated with the G1 arrest
at 24 h. Conversely, CDDP increased the protein levels
of TP53 in both cell lines accompanied by an increase in
CDKN1A in SK-MEL-5 but not in SK-MEL-28. CDDP
also slightly decreased the protein levels of CDKN1B
in both cell lines. No differences were observed in
CDKN2B levels with any treatment.
We also assessed the effect of TSPC on the protein
levels of CDKs and cyclins involved in G1 phase and G1
to S phase transition of cell cycle. As shown in Fig. 2d,
drug treatments did not show any detectable change in
the protein levels of CDK2 and CDK4, and only a slight
increase in cyclin D1 with TSPC in SK-MEL-5 was ob-
served. On the other hand, cyclin E2 levels were strongly
increased by CDDP, and conversely reduced by TSPC in
both cell lines.
In order to assess the mechanism of action of CDDP
in the absence of TP53, we also examined the phosphor-
ylation state of CDK1 (cdc2), which have been shown to
be associated with S and G2/M arrest and with CDDP
mechanism of action. Western blot analysis showed that
CDDP treatment strongly induced the protein levels of
phospho-CDK1 in both cell lines, while TSPC had no
effect (Fig. 2d). Densitometric analysis of proteins from
Fig. 2d is show in Fig. 3.
TSPC inhibits CDK2-cyclin E via CDKN1A and CDKN1B
Since up-regulation in CKIs levels was observed, and
these proteins exert their inhibitory effect and G1 cell
cycle arrest by direct binding to CDK2-cyclin E
complexes, we next examined CDK2-CKIs binding by
immunoprecipitation assay. As shown Fig. 4, TSPC
treatment showed an increased binding of CDKN1A and
CDKN1B with CDK2 in both cell lines. CDDP also
showed an increased binding of CDKN1A, bigger than
that observed with TSPC in SK-MEL-5.
The inhibitory effect of CKIs on CDK-cyclin com-
plexes occurs in the nucleus, so we next examined by
immunofluorescence and confocal microscopy the
localization of CKIs in this cell lines. As shown in Fig. 5a,
both CDKN1A and CDKN1B were mainly localized in
the nucleus in untreated cells. TSPC exposure induced
an increase of CDKN1A and CDKN1B in the nucleus in
SK-MEL-5 and SK-MEL-28, while CDDP treatment
seemed to slightly modified CDKN1B levels in both cell
lines. No CDKN1A staining was perceivable in SK-MEL-
28 in control and CDDP-treated cells. Confocal images
matched the results obtained by western blot (Fig. 2d).
In addition, we determined the percentage of nuclear
CDKN1A and CDKN1B staining in cell lines exposed to
CDDP or TSPC. As shown in Fig. 5b, cells treated with
TSPC had a higher percentage of nuclear CDKN1A and
CDKN1B than cells treated with CDDP (SK-MEL-5:
CDKN1A 25.36 ± 11.53 vs 5.45 ± 4.16; CDKN1B 54.04 ±
10.36 vs 30.70 ± 8.85) (SK-MEL-28: CDKN1A 15.31 ±
5.28 vs 1.5 ± 0.63; CDKN1B 62.11 ± 10.50 vs 23.53 ±
8.31). No significant changes of CDKN1A and CDKN1B
subcellular location were observed after treatment with
CDDP. By contrast, a significant increase in the nuclear
staining of both CKIs after exposure to TSPC was seen.
TSPC in combination
Once analysed the effect of TSPC on cell cycle and cell
growth, we next examined how long this effect would
last. Cell treated with TSPC recovered a normal prolifer-
ation rate after drug removal. However, cell treated with
CDDP did not recover (Fig. 6a). Seeing these results, as
well as the differential effects in cell cycle, we thought it
could be interesting to explore evidences for synergism
using both drugs in combination. As shown in Fig. 6b,
addition of TSPC to CDDP increased cell death in a
dose dependent manner in both cell lines, being espe-
cially important in the case of SK-MEL-28 with TSPC
5 μM. In fact, the analysis of these drugs interaction by
the Chou-Talalay method showed that this increment in
cell death was due to a synergistic effect between the
drugs (CI < 1; logCI < 0) in SK-MEL-28 at almost every
dose and, in SK-MEL-5 at the highest doses of CDDP
(Fig. 6c). Due to this synergism, there was a favourable
DRI (DRI > 1; logDRI > 0) in CDDP dose and in some
doses of TSPC in SK-MEL-5 and in both CDDP and
TSPC in SK-MEL-28 (Fig. 6d).
Taking into consideration this synergism we studied
whether cells treated with both drugs in combination
were able to recover after drug removal. For this purpose
we treated cells with CDDP at a dose lower than their
respective IC50: 1 μM (SK-MEL-5) or 3 μM (SK-MEL-
28), and TSPC 1 or 5 μM. In all the cases cells recovered
in the same way (Fig. 6e).
Discussion
Platinum complexes are widely used in cancer therapy.
The successful clinical applications of CDDP have in-
spired the synthesis and investigation of numerous
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platinum compounds as drug candidates. All the com-
mercially available platinum compounds are based in a
cis-isomerism.
In this study, the cellular and molecular effects of the
trans-platinum derivative TSPC were investigated and
directly compared with those of CDDP in SK-MEL-5
and SK-MEL-28 melanoma cell lines. The choice of
these cell lines were made on the basis of TP53 status,
and in our previous cytotoxicity results in a panel of
different cell lines [14].
TSPC showed to be as active as CDDP in SK-MEL-5
and more active in SK-MEL-28, the TP53 mutant line.
TP53 plays a very important role in CDDP cytotoxicity
[20], so it is not surprising that a TP53 mutant line show
some resistance to this drug [21, 22]. On the other hand,
and according to the results obtained in this work, TSPC
mode of action is clearly TP53-independent, as there is
no change in this protein levels after TSPC treatment,
neither in SK-MEL-5 nor in SK-MEL-28 cell lines.
Upon 24 h incubation with TSPC, cells were arrested
in G1 phase that suggest cell cycle delay for a DNA
damage response, DNA repair and/or apoptosis. One
goal of this study was to define the cell cycle regulatory
pathway responsible for the G1 arrest. The results ob-
tained in these two cell lines with different TP53 status
show that TSPC inhibits cell proliferation through cell
cycle arrest at G1 phase, likely due to the up-regulation
of CDK inhibitors CDKN1A and CDKN1B. Progression
through the G1 phase of the cell cycle is controlled by
CDK4-cyclin D complexes, while CDK2-cyclin E com-
plexes are required for proper G1/S transition and initi-
ation of S [23]. CDKs are negatively regulated by the
Fig. 3 Quantification of effect of CDDP and TSPC in cell cycle regulatory proteins TP53, CDKN1A, CDKN1B, CDKN2B, CDK2, CDK4, CCND1, CCNE2,
and P-CDK1 as determined by Western blot analysis of three independent experiments
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binding of CDK inhibitors. INK4 family inhibitors, as
CDKN2B, prevent cyclin D binding to CDK4, while
CDKN1A and CDKN1B bind to CDK2-cyclin E com-
plexes and inhibit CDK2 activity [24]. Our results
showed that neither CDK4, nor cyclin D1, nor CDKN2B
were affected by TSPC in SK-MEL-28 cells. Only a slight
increase in cyclin D1 was observed in SK-MEL-5 cells
but such levels might be insufficient to induce G1 pro-
gression effectively. However, CDKN1A and CDKN1B
protein levels were clearly enhanced after TSPC treat-
ment, and cyclin E2 levels were reduced in both cell
lines. Besides, co-immunoprecipitation assays showed
that both CDKN1A and CDKN1B bind to CDK2 after
TSPC treatment. Thus, it can be inferred that TSPC
induces G1 arrest in SK-MEL-5 and SK-MEL-28, via
CDKN1A and CDKN1B binding to CDK2-cyclin E
complexes in a TP53-independent manner (Fig. 7). The
cell cycle arrest is a common cellular response to DNA
damage and is viewed as a delay period in DNA replica-
tion during which the cell can attempt to repair the
damage. If this attempt fails, cell death pathways will be
activated [25, 26]. Our present findings indicate that the
G1 arrest is associated with an induction of CDKN1A
and CDKN1B proteins, and that this response is also
seen in melanoma cells containing TP53 mutated.
On the other hand, cells incubated with CDDP were
arrested in S and G2/M phase. Several reports have previ-
ously described that CDDP induces S- and G2/M-phase
arrests in a sequential manner [27]. These arrests are asso-
ciated with phosphorylation and proteosomal degradation
of CDC25 phosphatase, with the consequence that CDK
within the CDK2/cyclin A and CDK1/cyclin B complexes
remain in the inhibitory tyrosine phosphorylated state
[28]. Besides, CDKN1A can bind these CDKs and inhibit
these complexes [29], and as an inhibitor of CDC2 phos-
phorylation, CDKN1A can be involved in both G1 and G2
cell cycle arrest [30]. Our data from the present study are
in line with these previously published studies as CDK1
remain phosphorylated after CDDP treatment, and
CDKN1A binds to and inhibit CDK2. However, this set-
ting is different to that of TSPC, where CDC2 remains
hypophosphorylated. So, it seems that TSPC has a differ-
ent mode of action from that of CDDP.
The cell cycle regulatory function of both CDKN1A
and CDKN1B is associated with its nuclear localization,
but the protein can also localize in the cytoplasm where
they could exert different functions [31]. In the nucleus,
in addition to the regulation of the cell cycle progres-
sion, CDKN1A and CDKN1B are also involved in a
variety of transcriptional responses [32]. In the cyto-
plasm, CDKN1A can initiate antiapoptotic responses by
inhibiting proapoptotic kinase ASK1 [33] or by binding
to procaspase 3, thus preventing its proteolytic activa-
tion [34]. In a more general sense, it has been suggested
that the subcellular localization of CDKN1A defines its
function as a tumor suppressor (nuclear localization) or
oncoprotein (cytoplasmic localization) [32]. Indeed,
some human cancers display elevated levels of cytoplas-
mic CDKN1A or cytoplasmic CDKN1B, which is associ-
ated with poor prognosis [35–38], and badly response to
cisplatin based treatment [39, 40]. In our experiments,
the increased nuclear localization of CDKN1A and
CDKN1B in both melanoma cell lines after TSPC treat-
ment supports the antitumor activity of this compound.
Recovery experiments showed that while CDDP effect,
at least at IC50 dose, was permanent, TSPC treatment
Fig. 4 Co-immunoprecipitation assay of the interaction between CDK2 and CDKN1A, and CDK2 and CDKN1B in SK-MEL-5 and SK-MEL-28 cell lines
after CDDP and TSPC exposure. Quantification of CDKN1A and CDKN1B binds to CDK2, detected in co-immunoprecipitated products. (*, p < 0.05)
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was transitory. This is not necessarily a negative result,
but it implies that TSPC treatment should be frequent.
Thus, in regard to clinical treatment, it would be useful to
find an easy and sequentially way of TSPC administration.
CDDP is one of the most potent antitumor agents
known. However, toxicity and resistance are major limi-
tations of CDDP-based chemotherapy [1, 2]. Thus, the
potential for use of TSPC in combination with CDDP
was explored in terms of eventual synergism. In both
cell lines tested, our data show a synergistic effect and a
favorable DRI when cells are simultaneously treated with
both CDDP and TSPC, which could lead to resistance
minimization. This synergy is likely to be due to the
mechanistic differences between CDDP and TSPC.
Fig. 5 Cellular distribution of CDKN1A and CDKN1B in melanoma cell lines and its alteration after CDDP or TSPC treatment. a Subcellular
distribution of CDKN1A and CDKN1B in SK-MEL-5 and SK-MEL-28 cells, after CDDP and TSPC treatment assessed by confocal microscopy. First and
fourth columns: nuclei stained with DAPI; Second and fifth columns: CDKN1A (up) and CDKN1B (down) proteins stained with specific antibody
and secondary antibody conjugated with Alexa Fluor 488; Third and sixth columns: colocalization. b Quantitative analysis of nuclear CDKN1A (left)
and CDKN1B (right) staining in melanoma cell lines. Staining cells were counted at 200 ×magnification from six to ten randomly selected fields.
Total 100 cells were counted in each experiment. (*, p < 0.05)
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Fig. 6 Effects of CDDP and TSPC combined treatment. a Cell recovery after treatment removal. Cell growth was assessed for 7 days in cells
treated with either CDDP (triangles) or TSPC (circles) at their corresponding IC50 for 72 h followed by drug removal. Untreated cells were used as
control (squares). b Cell viability with drug treatment combination. Viability after treatment with different doses of CDDP ranging from 0.5 to
10 μM combined with TSPC 1 μM (right side-up triangles) or 5 μM (upside-down triangles). Cells just treated with CDDP were used as control
(squares). c Fa-log CI plot. The line represents the additive effect and all the points under it show synergism. d Fa-log DRI plot. The line separates
the favourable dose reduction (up) from the unfavourable (down). e Cell recovery after combination treatment removal. Clear shape symbol:
SK-MEL-5; Dark shape symbol: SK-MEL-28
Fig. 7 TSPC induces cell cycle G1 arrest probably mediated by CDKN1A and CDKN1B CKIs in a TP53-independent manner, while CDDP induces S
and G2/M arrest via TP53/CDKN1A pathway in SK-MEL-5, and preventing dephosphorylation of CDK1 in both cell lines
Agudo-López et al. Molecular Cancer  (2017) 16:45 Page 9 of 11
Conclusions
In this study we present a new promising TSPC compound
with in vitro antitumor activity against SK-MEL-5 and SK-
MEL-28 melanoma cell lines, with a different mechanism of
action that of CDDP. From our results it can be inferred that
TSPC induces cell cycle G1 arrest probably mediated by
CDKN1A and CDKN1B inhibitors in a TP53-independent
manner. CDK2-cyclin E complexes are required for G1/S
transition. By co-immunoprecipitation assays, we show that
CDKN1A and CDKN1B bind to CDK2 after TSPC treat-
ment, inhibiting CDK2 activity. Besides, synergy between
TSPC and CDDP facilitates its potential use for co-treatment
to reduce toxicity and resistance against CDDP. On the other
hand, TSPC remains a promising lead compound for the
generation of novel drug candidates with different cytotox-
icity profiles from those of CDDP. Moreover, these results
could have therapeutic implications for TSPC, because the
majority of human solid tumors contain a mutant TP-53 or
deleted TP53 gene and are inherently resistant to commonly
used DNA-damaging agents.
Abbreviations
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